GLENMARK 
Glenmark Pharmaceuticals Ltd
How do you think glenmark will perform against the NIFTY? Pick this stock
CAPITAL4 COMMUNITY
All: Members who that have picked this stock: 74
68 outperforms
6 underperforms
Stars: Top Investors who have picked this stock: 0
0 outperforms
0 underperforms
CLASSIFICATION | SECTOR | INDUSTRY |
|---|---|---|
| Primary | Pharma & Healthcare | Pharmaceuticals |
SNAPSHOT
- BSE Code / NSE Ticker
- 532296 / GLENMARK
- Last traded time
- 2012-05-23 15:59:09
- Last traded on
- BSE
- Intra-day Low / High
- 345.0 / 359.4
- 52w closing Low / High
- 272.1 / 365.4
- Today Volume
- 940,179
- 30d avg Daily Volume
- 1,056,128
- Market Cap
- INR 9,628.4 cr
- P/E Ratio TTM
- 36.28
- Historical Performance
- Today
- Weekly
- Monthly
- 3 Months
- 1 Year
- -0.3%
- 2.3%
- 10.0%
- 14.7%
- 24.8%
valuation snapshotpeer comparisonfinancialsshare holdingmf holdingcommunity picksbrokerage picks
| Ticker | Audited | MCap | Total Assets | Net Sales | Adj PAT | Op Margin | Adj Net-Margin | ROCE | Adj P/E(TTM) | P/Book | Debt/MCap |
|---|---|---|---|---|---|---|---|---|---|---|---|
| CADILAHC | 2011 | 15,217.3 | 2,653.9 | 2,176.2 | 610.6 | -7.7% | 28.1% | 27.6% | 23.1 | 7.3 | 0.0 |
| DIVISLAB | 2011 | 12,270.1 | 1,851.1 | 1,305.4 | 435.6 | 36.6% | 33.4% | 28.0% | 22.5 | 6.7 | 0.0 |
| GLENMARK | 2011 | 9,656.9 | 3,126.0 | 1,201.4 | 212.2 | 22.4% | 17.7% | 10.9% | 36.4 | 4.9 | 0.1 |
| WOCKPHARMA | 2011 | 7,855.1 | 2,568.6 | 1,736.9 | -132.1 | 2.2% | -7.6% | 4.0% | 27.3 | 11.7 | 0.2 |
| PIRHEALTH | 2011 | 7,158.2 | 11,984.8 | 1,585.4 | 277.9 | -12.1% | 17.5% | 139.3% | 54.7 | 0.6 | 0.0 |
| TORNTPHARM | 2011 | 5,208.8 | 1,665.1 | 1,744.1 | 285.3 | 15.2% | 16.4% | 24.8% | 14.4 | 4.8 | 0.1 |
| AVENTIS | 2010 | 4,822.4 | 1,014.1 | 1,085.0 | 155.2 | 2.8% | 14.3% | 31.2% | 26.7 | 4.8 | 0.0 |
| ASTRAZEN | 2011 | 4,676.9 | 179.7 | 593.2 | 64.1 | 15.4% | 10.8% | 64.8% | 236.5 | 26.0 | 0.0 |
| BIOCON | 2011 | 4,286.0 | 2,115.5 | 1,531.6 | 459.5 | 28.1% | 30.0% | 25.8% | 16.8 | 2.2 | 0.0 |
| IPCALAB | 2011 | 4,257.1 | 1,584.7 | 1,921.4 | 263.9 | 14.1% | 13.7% | 24.8% | 15.6 | 4.0 | 0.1 |
| STAR | 2010 | 3,910.6 | 2,648.0 | 504.0 | 31.2 | -4.9% | 6.2% | 7.4% | 60.4 | 2.8 | 0.3 |
| PFIZER | 2011 | 3,515.7 | 1,163.4 | 1,169.6 | 228.6 | 11.7% | 19.5% | 29.7% | 19.0 | 3.0 | 0.0 |
| MATRIXLABS | 2011 | 3,273.2 | 2,469.0 | 2,853.0 | 402.7 | 12.3% | 14.1% | 28.2% | 18.9 | 2.0 | 0.3 |
| AUROPHARMA | 2011 | 3,206.5 | 4,887.3 | 4,082.7 | 614.8 | 15.1% | 15.1% | 20.0% | 10.0 | 1.2 | 0.7 |
| ABBOTINDIA | 2010 | 3,061.9 | 305.4 | 1,036.0 | 61.0 | 3.2% | 5.9% | 30.9% | 26.1 | 10.0 | 0.0 |
CAPITAL4 COMMUNITY
STOCK SCREENERS
INDIA CAPITAL MARKETS
GLENMARK IN THE NEWS
- May-11 10:40 Glenmark Pharmaceuticals allots shares
- May-08 17:06 Glenmark Pharmaceuticals recommends dividend
- May-04 11:30 Glenmark Pharmaceuticals to announce financial results
- Apr-09 10:40 Glenmark Generics receives ANDA approval for Norgestimate and Ethinyl Estradiol tablets
- Apr-03 11:31 Glenmark Generics receives ANDA approval for Desogestrel & Ethinyl Estradiol tablets
- Mar-16 16:28 Glenmark Pharmaceuticals allots equity shares
- Mar-07 10:57 Glenmark Generics receives USFDA approval for Imiquimod Cream
- Mar-01 16:42 Glenmark Generics receives ANDA approvals for Ciclopirox Gel 0.77% and Levonorgestrel & Ethinyl Estradiol Tablets
- Feb-14 16:58 Glenmark Pharmaceuticals allots shares
- Feb-14 11:28 Glenmark's novel molecule 'GRC 17536' successfully completes Phase I trials in Europe
TOP BLOGS
- Advice for – Tuesday, May 22, 2012
by ABHISHEK-PARAKH
(Recommendations: 6) - Money can be made in all market conditions
by ASHOKSHARMA
(Recommendations: 7) - The problem with historical returns
by ROHIT CHAUHAN
(Recommendations: 9) - Markets: What next?
by Nishit_Vadhavkar
(Recommendations: 8) - Nifty – RSI at sub 30. Highly Oversold – Bottoming out in next few sessions
by NOORESH MERANI
(Recommendations: 9) - Follow up: Gujarat reclaim & rubber products ltd
by ROHIT CHAUHAN
(Recommendations: 9) - Negative news drags the markets down
by Nishit_Vadhavkar
(Recommendations: 7) - Option strategy worked will in such unpredictable market
by ASHOKSHARMA
(Recommendations: 8) - Sensex- Technical Outlook and Trading Levels, 8 April 2012
by D_Sathiamoorthy
(Recommendations: 5) - Insourcing vs. outsourcing government functions: A setback for public sector production of elementary education
by AJAY SHAH
(Recommendations: 7) - Crucial Week Ahead
by Nishit_Vadhavkar
(Recommendations: 8)
Company and Mutual Fund Finder
| Company: | 3ABCDEFGHIJKLMNOPQRSTUVWXYZ |
| Indices: | NIFTY | SENSEX | BSE 100 | BSE 200 | BSE 500 | BSE MIDCAP | BSE SMALLCAP | BSE AUTO | BSE BANKEX | BSE CD | BSE CG | BSE FMCG | BSE HC | BSE IT | BSE METAL | BSE OIL | BSE POWER | BSE PSU | BSE REALTY | BSE TECK | BSE DOLLEX | DOLLEX 100 | DOLLEX 200 | NIFTY JUNIOR | CNX MIDCAP | NIFTY MID50 | BANK NIFTY | CNX IT | CNX100 | CNX 500 | CNX DEFTY |
| Mutual Funds: | AIG Global Investment | AXIS | Baroda Pioneer | Benchmark | Bharti AXA | Birla Sun Life | Canara Robeco | Deutsche | DSP BlackRock | Edelweiss | Escorts | Fidelity | Fortis | Franklin Templeton | HDFC | HSBC | ICICI Prudential | IDBI | IDFC | ING | JM Financial | JP Morgan | Kotak Mahindra | L&T | LIC | Mirae Asset | Morgan Stanley | Motilal Oswal | Peerless | Pramerica | PRINCIPAL | Quantum | Reliance | Religare | Sahara | SBI | Shinsei | Sundaram BNP Paribas | Tata | Taurus | UTI |